Algenscribe I Genome Editing I Biotechnology

Reach the full potential of genome editing

AlgenScribe is a biotechnology company developing a genome editing platform to improve human health.

Company

Genome editing has the potential to revolutionize the way we cure severe diseases.

Algenscribe is a Biotechnology company developing a genome editing platform to improve human health.

Our strategy is to apply a unique toolbox for precise genome editing.

Our mission is to translate our technologies into therapeutics.

Gene
Therapy

Cell
engineering
tools

Biologics

Molecular Diagnostics

Genome
Editing

Company

Science

The foundation of our technologies is based on more than 10 years of development performed by Algentech in plant cell models.

Our platform possesses unique abilities to increase the efficiency of homologous recombination and addresses some limitations related to nuclease-based genome editing.

DNA is cut in a targeted site by molecular scissors (nucleases).

The cell repairs this break with 2 processes:

Non-homologous End Joining (NHEJ) or Homology-Directed Repair (HDR).

Gene inactivation

NHEJ

NHEJ is naturally more efficient than HDR

HDR

Module 1: Amplified donor DNA

guided to the insertion site

Mutations

Gene repair by HDR

Module 2: Enzyme to foster HDR

Management team

Frédéric Zampatti

Co-founder & CEO

M. Zampatti has 15 years of experience in supporting and financing innovative companies.

He financed and support for two seed funds various companies in the fields of biotechnology and diagnostics. Frédéric was a project manager at Genopole (Evry) and has an experience of deputy general manager in the start up Nutrivercell (sold to EA pharma group in 2017). He is graduated from Toulouse Business School.

Dr Isabelle Malcuit

Scientific co Founder

Dr Malcuit holds a PhD in plant virology received in 1998 from the department of genetics, Trinity College (Dublin, Ireland). Dr Malcuit has extensive experience in genetics and biotechnology. Prior to founding Algentech, she held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of the programme for functional genomics using VIGS (Virus-Induced Gene Silencing). She is co-inventor on 7 patent families owned by Algentech.

Dr Alexander Sorokin

Scientific co Founder

Dr Sorokin has more than 20 years’ experience in genetics, agronomy and biotechnology. He obtained his PhD in plant genetics obtained in 1991 from the school of Agronomy in Minsk for his work on wheat and triticale genetics. Prior to founding Algentech he held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of technology development and consultant at Plant Bioscience Ltd (Norwich, UK). He is co-inventor on 7 patent families owned by Algentech.

Partnerships